We are live on ! Find out more
FP

Flagship Pioneering Portfolio holdings

AUM $1.54B
1-Year Est. Return 86.39%
This Fund
S&P 500
This Quarter Est. Return
+20.53%
1 Year Est. Return
+86.39%
3 Year Est. Return
-13.28%
5 Year Est. Return
-50.7%
10 Year Est. Return
+414.55%
AUM
$2.64B
AUM Growth
+$595M
Cap. Flow
+$220M
Cap. Flow %
8.32%
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
KLDO
Kaleido Biosciences, Inc. Common Stock
KLDO
+$239M

Top Sells

Rank Stock Value
1
DNLI icon
Denali Therapeutics
DNLI
+$19.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
1
Moderna
MRNA
$57.4B
$1.2B 45.29%
58,807,379
– –
RUBY
2
DELISTED
Rubius Therapeutics, Inc
RUBY
$693M 26.23%
38,296,526
– –
KLDO
3
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$252M 9.53%
+17,360,710
New +$239M
DNLI icon
4
Denali Therapeutics
DNLI
$3.26B
$186M 7.04%
8,005,747
-913,002
-10% -$19.1M
EVLO
5
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$146M 5.52%
911,670
– –
MCRB icon
6
Seres Therapeutics
MCRB
$46.2M
$87.1M 3.3%
634,144
– –
QTRX icon
7
Quanterix
QTRX
$129M
$52.4M 1.99%
2,030,495
– –
SYRS
8
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$29.3M 1.11%
320,444
– –

Similar funds

SPC
Stony Point Capital New York $1.54B AUM 54.05% 1-Year Est. Return
AWC
Abundance Wealth Counselors State College, Pennsylvania $1.54B AUM 31.07% 1-Year Est. Return
SMC
Smith, Moore & Co Clayton, Missouri $1.54B AUM 24.82% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.54B AUM 30.95% 1-Year Est. Return
BOF
Bank of Finland Helsinki, Finland $1.54B AUM 15.84% 1-Year Est. Return
KCM
Kanawha Capital Management Richmond, Virginia $1.54B AUM 21.3% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.54B AUM 27.61% 1-Year Est. Return
HCM
Hollencrest Capital Management Newport Beach, California $1.54B AUM 30.1% 1-Year Est. Return

Flagship Pioneering's Q1 2019 Portfolio in Review

As of Q1 2019, Flagship Pioneering held 8 positions worth $2.64B, up 29% from $2.05B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Flagship Pioneering deployed $220M of net new capital in Q1 2019, opening 1 new position. Its largest new stake was Kaleido Biosciences, Inc. Common Stock: 17,360,710 shares worth $252M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Denali Therapeutics, an estimated $19.1M trimmed.

  • Flagship Pioneering's largest Q1 2019 buy was Kaleido Biosciences, Inc. Common Stock: 17,360,710 shares worth $252M.
  • Flagship Pioneering's biggest Q1 2019 reduction was Denali Therapeutics, cutting an estimated $19.1M.
  • Flagship Pioneering's ten largest holdings make up 100% of its $2.64B portfolio in Q1 2019.
  • Flagship Pioneering opened 1 new position and closed 0 in Q1 2019.
  • Flagship Pioneering's portfolio value rose 29% quarter-over-quarter to $2.64B.

Based on Flagship Pioneering's 13F filing for Q1 2019, filed 14 May 2019.